Chris Schott
Stock Analyst at JP Morgan
(0.52)
# 1648
Out of 5,291 analysts
127
Total ratings
50.00%
Success rate
5.79%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Gilead Sciences | Maintains: Overweight | 120 130 | 111.78 | 16.3% | 5 | Mar 27, 2025 | |
Amneal Pharmaceutica... | Upgrades: Overweight | 9 12 | 8.28 | 44.93% | 2 | Feb 24, 2025 | |
AbbVie | Maintains: Overweight | 210 200 | 205.15 | -2.51% | 2 | Nov 13, 2024 | |
Biogen | Maintains: Neutral | 220 210 | 138.4 | 51.73% | 3 | Nov 4, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1200 1150 | 637.75 | 80.32% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 16 18 | 15.05 | 19.6% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 415.8 | 38.29% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 163.04 | 41.07% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 820.02 | 34.14% | 19 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 14.52 | 37.74% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 28.07 | 46.06% | 8 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 31.36 | 33.93% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 306.93 | -12.03% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 25.19 | 34.97% | 7 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 89.18 | 40.17% | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 8.68 | 61.29% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 0.84 | 1209.52% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 10.39 | 92.49% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 60.09 | 29.81% | 4 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 6.06 | 15576.57% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 24.93 | 100.56% | 3 | Nov 2, 2018 |